Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Atea Pharmaceuticals, Inc. AVIR
$3.25
-$0.06 (-1.96%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
277110820.00000000
-
week52high
9.79
-
week52low
2.94
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.24350500
-
EPS
-1.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Underweight | 15 авг 2022 г. |
| JP Morgan | Neutral | Neutral | 02 мар 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 01 мар 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 16 февр 2022 г. |
| Morgan Stanley | Underweight | Equal-Weight | 06 янв 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 27 янв 2023 г. |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Foster Wayne | A | 140000 | 140000 | 31 янв 2023 г. |
| Foster Wayne | A | 100000 | 100000 | 31 янв 2023 г. |
| Sommadossi Jean-Pierre | A | 728600 | 728600 | 31 янв 2023 г. |
| Sommadossi Jean-Pierre | A | 520400 | 520400 | 31 янв 2023 г. |
| Horga Maria Arantxa | A | 174500 | 174500 | 31 янв 2023 г. |
| Horga Maria Arantxa | A | 124600 | 124600 | 31 янв 2023 г. |
| Corcoran Andrea | A | 186300 | 186300 | 31 янв 2023 г. |
| Corcoran Andrea | A | 133100 | 133100 | 31 янв 2023 г. |
| Vavricka John | A | 140000 | 140000 | 31 янв 2023 г. |
| Vavricka John | A | 100000 | 100000 | 31 янв 2023 г. |
Новостная лента
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
GlobeNewsWire
07 февр 2023 г. в 07:00
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET.
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 07:00
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA.
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
GlobeNewsWire
22 ноя 2022 г. в 07:00
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29 at 9:40 a.m. ET.
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
10 ноя 2022 г. в 13:32
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
Zacks Investment Research
10 ноя 2022 г. в 11:18
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.